Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

DBV Tech completes enrollment in mid-stage study of treatment for milk protein allergy

Published 11/08/2016, 07:53 AM
DBV Tech completes enrollment in mid-stage study of treatment for milk protein allergy
DBVT
-
  • Enrollment has been completed in a Phase 2b clinical trial, MILES, assessing DBV Technologies ' (NASDAQ:DBVT) Viaskin Milk for the treatment of patients (ages 2 - 17) with IgE-mediated cow's milk protein allergy (CMPA). Approximately 176 children have been randomized 1:1:1:1 to receive one of three doses of Viaskin Milk (150 ug, 300 ug, 500 ug) or placebo for 12 months. The primary endpoint is the response rate at Month 12. The blinded part of the study should be completed in H2 2017.
  • Viaskin Milk is a patch worn on the skin that contains the milk antigen in dry form. It creates a condensation chamber with skin which solubilizes the antigen allowing it to penetrate the upper layers of the epidermis where particular cells called Langerhans cells are located. These dendritic cells are major components of the skin immune system and play a key role in adaptive immune response. Exposing these cells to a particular antigen promotes immunity to the antigen.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.